is the glp 1 shortage over What happens when demand outpaces supply? GLP-1 transformed the market., Caleb Silver breaks down how the FDA's shortage designation opened the door to compounded GLP-1s, increased The FDA says the shortage

This approach is particularly appropriate for patients with obesity and symptomatic cholelithiasis who would benefit from both interventions

Nausea is the most frequently reported side effect, affecting 40 to 50 percent of patients at some point during treatment, typically during dose escalation

Astrup A, Carraro R, Finer N, et al

But, theres another frontier for the injectables: treating polycystic ovarian syndrome (PCOS)

Recent studies have shown that the browning of adipose tissue, including brown remodelling of WAT and promotion of the brown adipose tissue (BAT) function, could counteract obesity (reviewed in Bartelt and Heeren [10])